Anders K. Nilsson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anders K. Nilsson has a total of 124 co-authors. Here are the top co-authors by number of shared publications:
- Ann Hellström
Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
17 shared publications Ann Hellström
The Sahlgrenska Centre for Pediatric Ophthalmology Research, Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
9 shared publicationsKarin Sävman
Region Västra Götaland, Dept of Neonatology, The Queen Silvia Children′s Hospital, Sahlgrenska University Hospital, Gothenburg, Sweden
9 shared publicationsUlrika Sjöbom
Institute of Health and Care Sciences, University of Gothenburg Sahlgrenska Academy, Gothenburg, Sweden
9 shared publicationsGunnel Hellgren
The Sahlgrenska Centre for Pediatric Ophthalmology Research, Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
7 shared publications- Ulrika Sjöbom
Department of Clinical Neuroscience at the Institution of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg , Gothenburg 405 30
7 shared publications
Latest Publications
- Open Access
- 23 June 2026
- Published by Wiley in Acta Ophthalmologica
Childhood ocular safety after postnatal exposure to topical dexamethasone during retinopathy of prematurity screening
Purpose: Dexamethasone eye drops are being introduced off‐label to prevent progression of severe retinopathy of prematurity (ROP). We evaluated ophthalmologic outcomes in early childhood after postnatal topical dexamethasone exposure in pre‐term infants at a standardized follow‐up examination. Methods: This prospective cross‐sectional follow‐up study included preterm infants born between 2019 and 2022 in the Västra Götaland region, Sweden, who received topical dexamethasone off‐label during ROP screening. As a follow‐up, a single standardized ophthalmological examination assessed visual acuity, refractive error, ocular motility, intraocular pressure (IOP) and structural ocular abnormalities. Results: Twenty‐four infants (median gestational age 25.0 weeks, range 22.6–27.7 weeks; 58% male) were examined at a median age of 2.9 years (range 1.1–5.0 years). Dexamethasone eye drops were initiated mainly for severe ROP at a median postmenstrual age of 35.1 weeks (range 32.0–52.0 weeks) and given for a median duration of 28 days (range 4–136 days). Median IOP was 18.9 mmHg (range 9.0–22.3 mmHg), and no child showed clinical signs of glaucoma. One child had a unilateral peripheral lens opacity without visual significance. No other ocular structural abnormalities were detected. Strabismus was detected in 2 (8%) of the children, and 3 (12%) had refractive errors. Conclusion: Preliminary data from extremely preterm infants exposed to off‐label topical dexamethasone during ROP screening showed no clinically significant ocular adverse effects at standardized early childhood follow‐up. Rates of strabismus and refractive errors were lower than expected. Larger studies with longer follow‐up are needed to further assess ocular and systemic safety.
- 23 June 2026
- Published by Wiley in Acta Ophthalmologica
Open AccessChildhood ocular safety after postnatal exposure to topical dexamethasone during retinopathy of prematurity screening
Purpose: Dexamethasone eye drops are being introduced off‐label to prevent progression of severe retinopathy of prematurity (ROP). We evaluated ophthalmologic outcomes in early childhood after postnatal topical dexamethasone exposure in pre‐term infants at a standardized follow‐up examination. Methods: This prospective cross‐sectional follow‐up study included preterm infants born between 2019 and 2022 in the Västra Götaland region, Sweden, who received topical dexamethasone off‐label during ROP screening. As a follow‐up, a single standardized ophthalmological examination assessed visual acuity, refractive error, ocular motility, intraocular pressure (IOP) and structural ocular abnormalities. Results: Twenty‐four infants (median gestational age 25.0 weeks, range 22.6–27.7 weeks; 58% male) were examined at a median age of 2.9 years (range 1.1–5.0 years). Dexamethasone eye drops were initiated mainly for severe ROP at a median postmenstrual age of 35.1 weeks (range 32.0–52.0 weeks) and given for a median duration of 28 days (range 4–136 days). Median IOP was 18.9 mmHg (range 9.0–22.3 mmHg), and no child showed clinical signs of glaucoma. One child had a unilateral peripheral lens opacity without visual significance. No other ocular structural abnormalities were detected. Strabismus was detected in 2 (8%) of the children, and 3 (12%) had refractive errors. Conclusion: Preliminary data from extremely preterm infants exposed to off‐label topical dexamethasone during ROP screening showed no clinically significant ocular adverse effects at standardized early childhood follow‐up. Rates of strabismus and refractive errors were lower than expected. Larger studies with longer follow‐up are needed to further assess ocular and systemic safety.
- Open Access
Enteral docosahexaenoic and arachidonic acid supplementation and retinopathy of prematurity: a re-analysis of randomized controlled trials in preterm infants
Background: A recent meta-analysis by Dang et al. [1] concluded that enteral supplementation with docosahexaenoic acid (DHA), with or without arachidonic acid (ARA) did not significantly affect retinopathy of prematurity (ROP) outcomes in preterm infants. Of four eligible trials that supplemented both DHA and ARA, only two contributed to each ROP outcome analyzed, and severe ROP was not assessed. Methods: We replicated the eligibility criteria and search strategy of Dang et al ., restricted to trials that supplemented both DHA and ARA, and reanalyzed three ROP endpoints (any ROP, ROP requiring treatment, and severe ROP [stage 3 and/or treated]) using complete outcome records from all eligible trials. Crude risk ratios (RR) were pooled by Mantel-Haenszel fixed-effect meta-analysis. Gestational age-adjusted odds ratios (adjOR) were pooled on the log scale by inverse-variance random-effects meta-analysis with restricted maximum likelihood (REML) estimation of between-study variance and Hartung-Knapp confidence intervals. Results: Five trials were included; one trial was identified in our replicated search but was excluded by Dang et al . without a stated rationale. The pooled estimate for any ROP was consistent with Dang et al . (RR 0.87 [95% CI 0.71–1.08]; adjOR 0.70 [0.46–1.08]). For ROP requiring treatment, the crude RR suggested a lower risk but did not reach statistical significance (RR 0.60 [0.35–1.04]), whereas the gestational age-adjusted estimate indicated lower odds (adjOR 0.47 [0.23–0.94]). For severe ROP, DHA+ARA supplementation produced a significant protective effect in both unadjusted and adjusted models (RR 0.56 [0.36–0.86]; adjOR 0.42 [0.19–0.96]). Conclusions: When all eligible trials contribute to each endpoint and severe ROP is included as an outcome, enteral DHA+ARA supplementation reduces severe ROP and is associated with lower odds of ROP requiring treatment after adjustment for gestational age. These findings differ from the conclusions of Dang et al . and support reconsideration of DHA+ARA supplementation as a strategy to reduce sight-threatening ROP in preterm infants.
Open AccessEnteral docosahexaenoic and arachidonic acid supplementation and retinopathy of prematurity: a re-analysis of randomized controlled trials in preterm infants
Background: A recent meta-analysis by Dang et al. [1] concluded that enteral supplementation with docosahexaenoic acid (DHA), with or without arachidonic acid (ARA) did not significantly affect retinopathy of prematurity (ROP) outcomes in preterm infants. Of four eligible trials that supplemented both DHA and ARA, only two contributed to each ROP outcome analyzed, and severe ROP was not assessed. Methods: We replicated the eligibility criteria and search strategy of Dang et al ., restricted to trials that supplemented both DHA and ARA, and reanalyzed three ROP endpoints (any ROP, ROP requiring treatment, and severe ROP [stage 3 and/or treated]) using complete outcome records from all eligible trials. Crude risk ratios (RR) were pooled by Mantel-Haenszel fixed-effect meta-analysis. Gestational age-adjusted odds ratios (adjOR) were pooled on the log scale by inverse-variance random-effects meta-analysis with restricted maximum likelihood (REML) estimation of between-study variance and Hartung-Knapp confidence intervals. Results: Five trials were included; one trial was identified in our replicated search but was excluded by Dang et al . without a stated rationale. The pooled estimate for any ROP was consistent with Dang et al . (RR 0.87 [95% CI 0.71–1.08]; adjOR 0.70 [0.46–1.08]). For ROP requiring treatment, the crude RR suggested a lower risk but did not reach statistical significance (RR 0.60 [0.35–1.04]), whereas the gestational age-adjusted estimate indicated lower odds (adjOR 0.47 [0.23–0.94]). For severe ROP, DHA+ARA supplementation produced a significant protective effect in both unadjusted and adjusted models (RR 0.56 [0.36–0.86]; adjOR 0.42 [0.19–0.96]). Conclusions: When all eligible trials contribute to each endpoint and severe ROP is included as an outcome, enteral DHA+ARA supplementation reduces severe ROP and is associated with lower odds of ROP requiring treatment after adjustment for gestational age. These findings differ from the conclusions of Dang et al . and support reconsideration of DHA+ARA supplementation as a strategy to reduce sight-threatening ROP in preterm infants.
- Open Access
- 27 March 2026
- Published by Elsevier in Journal of Lipid Research
- Vol. 67 (5) , 101030
Low serum sphingosine-1-phospate and its chaperone ApoM associate with retinopathy of prematurity
- 27 March 2026
- Published by Elsevier in Journal of Lipid Research
- Vol. 67 (5) , 101030
Open AccessLow serum sphingosine-1-phospate and its chaperone ApoM associate with retinopathy of prematurity
- Open Access
- 19 January 2026
- Published by BMJ in Archives of Disease in Childhood - Fetal and Neonatal Edition
- Vol. 111 (4) , F344-F351
Effect of enteral arachidonic acid and docosahexaenoic acid supplementation on brain volumes at term in preterm infants: a secondary outcome analysis of a randomised controlled trial
Objective: Investigate whether enteral supplementation with arachidonic acid (AA) and docosahexaenoic acid (DHA), from birth to term-equivalent age (TEA), promotes brain maturation as a prespecified secondary outcome of a multicentre randomised controlled trial. Participants: 206 infants born at 22–28 weeks gestational age (GA) were randomised into intervention or control groups from three university hospitals in Sweden. Intervention: The intervention group received an oil with AA (100 mg/kg/d) and DHA (50 mg/kg/d) starting at birth until 40 weeks postmenstrual age (PMA) in addition to standard nutrition. Standard-of-care infants received standard nutrition according to national guidelines. Main outcome and measures: MRI volumetrics were defined a priori as a secondary outcome of the trial and included total brain, white and cortical grey matter, central structures and cerebellum. Univariable and multivariable linear regression models were used for comparisons. Results: MRI data in 117 infants had sufficient quality for inclusion (n=58 intervention). Birth weight, GA at birth, sex distribution, and PMA at MRI were similar in the groups. Infants receiving intervention had significantly larger white-matter volume at TEA, as compared with standard of care, in models adjusted for GA at birth, sex, study centre and PMA at MRI (β=6.8 cm 3 , 95% CI 0.7 to 12.9, p=0.028). The contribution of the intervention to white-matter volume corresponded to 10 days of prolonged gestation. Conclusion and relevance: Our findings in this hypothesis-generating study suggest that AA+DHA promotes white matter growth, which may protect the developing brain in this vulnerable population. Trial registration number: NCT03201588 .
- 19 January 2026
- Published by BMJ in Archives of Disease in Childhood - Fetal and Neonatal Edition
- Vol. 111 (4) , F344-F351
Open AccessEffect of enteral arachidonic acid and docosahexaenoic acid supplementation on brain volumes at term in preterm infants: a secondary outcome analysis of a randomised controlled trial
Objective: Investigate whether enteral supplementation with arachidonic acid (AA) and docosahexaenoic acid (DHA), from birth to term-equivalent age (TEA), promotes brain maturation as a prespecified secondary outcome of a multicentre randomised controlled trial. Participants: 206 infants born at 22–28 weeks gestational age (GA) were randomised into intervention or control groups from three university hospitals in Sweden. Intervention: The intervention group received an oil with AA (100 mg/kg/d) and DHA (50 mg/kg/d) starting at birth until 40 weeks postmenstrual age (PMA) in addition to standard nutrition. Standard-of-care infants received standard nutrition according to national guidelines. Main outcome and measures: MRI volumetrics were defined a priori as a secondary outcome of the trial and included total brain, white and cortical grey matter, central structures and cerebellum. Univariable and multivariable linear regression models were used for comparisons. Results: MRI data in 117 infants had sufficient quality for inclusion (n=58 intervention). Birth weight, GA at birth, sex distribution, and PMA at MRI were similar in the groups. Infants receiving intervention had significantly larger white-matter volume at TEA, as compared with standard of care, in models adjusted for GA at birth, sex, study centre and PMA at MRI (β=6.8 cm 3 , 95% CI 0.7 to 12.9, p=0.028). The contribution of the intervention to white-matter volume corresponded to 10 days of prolonged gestation. Conclusion and relevance: Our findings in this hypothesis-generating study suggest that AA+DHA promotes white matter growth, which may protect the developing brain in this vulnerable population. Trial registration number: NCT03201588 .
- Open Access
- 1 October 2025
- Published by Taylor & Francis in Journal of Blood Medicine
- Vol. ume 16, 483-492
Circulating CD34 Positive Cells and Immunological Responses in Extremely Preterm Infants
Background: The dynamic changes of the hematopoietic system during fetal development may be disrupted by preterm birth. Hematopoietic stem and progenitor cell (CD34+) levels are poorly investigated in preterm infants, particularly in relation to immune responses and morbidities. This is partly because of low blood volumes, which raise ethical concerns and limit specific sampling for research studies. To overcome this problem, we used residual blood from routine clinical testing to monitor CD34+ cell counts in the first months of life. Our aim was to characterize the dynamics of circulating CD34+ cells and explore associations with prenatal and postnatal clinical events. Methods: We retrieved residual blood samples from nine infants born < 28 weeks gestational age (GA), collected from birth through eight postnatal weeks. CD34+ cell count was assessed using flow cytometry. The number of nucleated red and white blood cells, and hemoglobin concentration were also measured. Results: Median (min-max) GA was 25+0 (22+3─27+5) weeks. CD34+ cell counts at birth ranged from 19 to 284 x 106 cells/L. Between days 0 and 1, CD34+ cell count increased in four infants and decreased in four. By day 7, the proportion of CD34+ of total nucleated blood cells was significantly lower than at birth (p=0.018). High inter- and intra-individual variability in CD34+ cell count was observed. Notably, the highest CD34+ cell levels coincided with maternal or infant infections. Conclusion: This pilot study demonstrates the feasibility of longitudinal monitoring of CD34+ hematopoietic stem and progenitor cells in extremely preterm infants using residual clinical blood samples. While limited by a small sample size, the study provides preliminary insights into early immune function and highlights directions for future research in larger cohorts.
- 1 October 2025
- Published by Taylor & Francis in Journal of Blood Medicine
- Vol. ume 16, 483-492
Open AccessCirculating CD34 Positive Cells and Immunological Responses in Extremely Preterm Infants
Background: The dynamic changes of the hematopoietic system during fetal development may be disrupted by preterm birth. Hematopoietic stem and progenitor cell (CD34+) levels are poorly investigated in preterm infants, particularly in relation to immune responses and morbidities. This is partly because of low blood volumes, which raise ethical concerns and limit specific sampling for research studies. To overcome this problem, we used residual blood from routine clinical testing to monitor CD34+ cell counts in the first months of life. Our aim was to characterize the dynamics of circulating CD34+ cells and explore associations with prenatal and postnatal clinical events. Methods: We retrieved residual blood samples from nine infants born < 28 weeks gestational age (GA), collected from birth through eight postnatal weeks. CD34+ cell count was assessed using flow cytometry. The number of nucleated red and white blood cells, and hemoglobin concentration were also measured. Results: Median (min-max) GA was 25+0 (22+3─27+5) weeks. CD34+ cell counts at birth ranged from 19 to 284 x 106 cells/L. Between days 0 and 1, CD34+ cell count increased in four infants and decreased in four. By day 7, the proportion of CD34+ of total nucleated blood cells was significantly lower than at birth (p=0.018). High inter- and intra-individual variability in CD34+ cell count was observed. Notably, the highest CD34+ cell levels coincided with maternal or infant infections. Conclusion: This pilot study demonstrates the feasibility of longitudinal monitoring of CD34+ hematopoietic stem and progenitor cells in extremely preterm infants using residual clinical blood samples. While limited by a small sample size, the study provides preliminary insights into early immune function and highlights directions for future research in larger cohorts.
- Open Access
- 20 February 2025
- Published by Wiley in Acta Paediatrica
- Vol. 114 (8) , 1831-1838
Ethical Biobanking in Extremely Preterm Infants: Lessons From the EPITOP Study
Aim: The Extremely Preterm Infant Target Optimise and Prevent (EPITOP) study aimed to develop an ethical and practical approach to biobanking salvaged residual blood samples from extremely preterm infants (< 28 weeks gestational age, GA) for biomarker research while minimising clinical risks and addressing ethical concerns. Methods: Initiated in collaboration with Sahlgrenska University Hospital and Biobank Väst, Region Västra Götaland, Sweden, residual blood samples were collected from infants admitted to the neonatal intensive care unit (NICU) from March 2020 to March 2024. Samples were ethically salvaged and biobanked following parental consent and in compliance with Sweden's Biobank Act. Results: Among 215 eligible infants (mean (GA) 25.4 weeks), 122 consents enabled the collection of 4238 residual samples, of which 92.5% were from blood gas analyses. Sample collection was highest during the first weeks of life, with a median of 35 samples per infant. A higher number of morbidities and lower GA were both associated with an increase in sample numbers. Plasma and whole blood aliquots were prepared and stored for future biomarker studies. Conclusion: The EPITOP study demonstrates the feasibility of ethically biobanking salvaged residual blood samples from extremely preterm infants. This approach minimises clinical risks while supporting biomarker discovery, providing a scalable model for neonatal research.
- 20 February 2025
- Published by Wiley in Acta Paediatrica
- Vol. 114 (8) , 1831-1838
Open AccessEthical Biobanking in Extremely Preterm Infants: Lessons From the EPITOP Study
Aim: The Extremely Preterm Infant Target Optimise and Prevent (EPITOP) study aimed to develop an ethical and practical approach to biobanking salvaged residual blood samples from extremely preterm infants (< 28 weeks gestational age, GA) for biomarker research while minimising clinical risks and addressing ethical concerns. Methods: Initiated in collaboration with Sahlgrenska University Hospital and Biobank Väst, Region Västra Götaland, Sweden, residual blood samples were collected from infants admitted to the neonatal intensive care unit (NICU) from March 2020 to March 2024. Samples were ethically salvaged and biobanked following parental consent and in compliance with Sweden's Biobank Act. Results: Among 215 eligible infants (mean (GA) 25.4 weeks), 122 consents enabled the collection of 4238 residual samples, of which 92.5% were from blood gas analyses. Sample collection was highest during the first weeks of life, with a median of 35 samples per infant. A higher number of morbidities and lower GA were both associated with an increase in sample numbers. Plasma and whole blood aliquots were prepared and stored for future biomarker studies. Conclusion: The EPITOP study demonstrates the feasibility of ethically biobanking salvaged residual blood samples from extremely preterm infants. This approach minimises clinical risks while supporting biomarker discovery, providing a scalable model for neonatal research.
- Open Access
- 4 December 2024
- Published by Elsevier in Chemosphere
- Vol. 369, 143854
Environmental concentrations of the fungicide tebuconazole alter microbial biodiversity and trigger biofilm-released transformation products
- 4 December 2024
- Published by Elsevier in Chemosphere
- Vol. 369, 143854
Open AccessEnvironmental concentrations of the fungicide tebuconazole alter microbial biodiversity and trigger biofilm-released transformation products
- Open Access
- 16 October 2024
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 8 (12) , bvae179
Postnatal Dysregulation of Androgens in Extremely Preterm Male Infants
Context Neurodevelopmental impairments are common among survivors of extremely preterm birth, particularly in males. Hyperactivation of the hypothalamic-pituitary-gonadal (HPG) axis has been suggested as an underlying cause, but this has been poorly investigated. Objective Establish levels and temporal changes in circulating androgens in extremely preterm infant males. Design and Participants Observational cohort study analyzing cord blood serum (n=25) and postnatal plasma (n=13) collected from day 0 until week 11 from infant males born at 22.8-27.9 weeks gestational age. Main outcome measures Testosterone and dihydrotestosterone (DHT) were determined using gas-chromatography mass-spectrometry, sex hormone-binding globulin (SHBG) with ELISA, and follicle-stimulating hormone (FSH) and luteinizing hormone (LH) with Luminex xMAP multiplex assay. Results Testosterone and DHT levels were higher on day 0 (median 4.27 and 0.30 ng/ml) than in cord blood (0.15 and 0.01 ng/ml), pin utero levels. FSH and LH showed similar postnatal patterns as the androgens. SHBG steadily increased over time, and as a result, the fraction of bioavailable testosterone declined with infant postnatal age. Conclusions The HPG axis is activated immediately after birth in extremely preterm infant males resulting in an androgen pulse occurring several months earlier than during a normal pregnancy. The long-term implications of high androgen exposure during a sensitive neurodevelopmental period warrant further studies.
- 16 October 2024
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 8 (12) , bvae179
Open AccessPostnatal Dysregulation of Androgens in Extremely Preterm Male Infants
Context Neurodevelopmental impairments are common among survivors of extremely preterm birth, particularly in males. Hyperactivation of the hypothalamic-pituitary-gonadal (HPG) axis has been suggested as an underlying cause, but this has been poorly investigated. Objective Establish levels and temporal changes in circulating androgens in extremely preterm infant males. Design and Participants Observational cohort study analyzing cord blood serum (n=25) and postnatal plasma (n=13) collected from day 0 until week 11 from infant males born at 22.8-27.9 weeks gestational age. Main outcome measures Testosterone and dihydrotestosterone (DHT) were determined using gas-chromatography mass-spectrometry, sex hormone-binding globulin (SHBG) with ELISA, and follicle-stimulating hormone (FSH) and luteinizing hormone (LH) with Luminex xMAP multiplex assay. Results Testosterone and DHT levels were higher on day 0 (median 4.27 and 0.30 ng/ml) than in cord blood (0.15 and 0.01 ng/ml), pin utero levels. FSH and LH showed similar postnatal patterns as the androgens. SHBG steadily increased over time, and as a result, the fraction of bioavailable testosterone declined with infant postnatal age. Conclusions The HPG axis is activated immediately after birth in extremely preterm infant males resulting in an androgen pulse occurring several months earlier than during a normal pregnancy. The long-term implications of high androgen exposure during a sensitive neurodevelopmental period warrant further studies.
- Open Access
- 3 April 2024
- Published by Elsevier in Clinical Nutrition
- Vol. 43 (5) , 1162-1170
Arachidonic acid and docosahexaenoic acid levels correlate with the inflammation proteome in extremely preterm infants
- 3 April 2024
- Published by Elsevier in Clinical Nutrition
- Vol. 43 (5) , 1162-1170
Open AccessArachidonic acid and docosahexaenoic acid levels correlate with the inflammation proteome in extremely preterm infants